Incyte (INCY) Tops Q4 EPS by 8c, Revenues Beat

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/25/2026

1. DECK
2. RNG
3. WDC
4. BMY
5. BYD
6. SPOT
7. WCN
8. FIX
9. TSCO
10. BE

Go back to Incyte (INCY) Tops Q4 EPS by 8c, Revenues Beat

Eli Lilly & Co. (LLY) & Incyte (INCY) Report Positive Top-Line Results from the North American Phase 3 Study (BREEZE-AD5) of Oral Selective JAK Inhibitor Baricitinib

February 12, 2020 5:54 AM EST

Eli Lilly (NYSE: LLY) and Company and Incyte (NASDAQ: INCY) announced that baricitinib met the primary endpoint in BREEZE-AD5, an investigational Phase 3, randomized, placebo-controlled study evaluating the safety and efficacy of baricitinib for the treatment of adult patients with moderate- to severe atopic dermatitis (AD). The primary endpoint was defined by the proportion of patients achieving at least a 75% or greater change from baseline in their Eczema Area and Severity Index (EASI) at Week 16.

Atopic dermatitis is chronic skin condition which affects approximately one to three percent of... More